

#13  
gnyPractitioner's Docket No. MPI95-015P1RCPA1DV1M

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David R. Phillips, et al  
Application No.: 09/801,089      Group No.: 1644  
Filed: March 08, 2001      Examiner: Not yet assigned  
For: MODULATION OF INTEGRIN-MEDIATED SIGNAL TRANSDUCTION

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 08 2003

REVOCATION OF PRIOR POWERS OF ATTORNEY  
AND APPOINTMENT OF NEW POWER OF ATTORNEY TECH CENTER 1600/2900

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Merger document filed with the United States Patent and Trademark Office on June 10, 2002, at Reel 012977, Frame 0516 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"  
Mailing Label No.

## TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: \_\_\_\_\_

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Scott A. Brown, Reg. No. 32,724; Carmen Pili Ekstrom, Reg. No. 34,981; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenko, Reg. No. 38,945, Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. P-52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 617-679-7336

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Jean M. Silveri

Title: Sr. Patent Counsel

Dated: January 3, 2003